Charlotte Gerd Hannibal1, Russell Vang2, Jette Junge3, Kirsten Frederiksen1, Anette Kjaerbye-Thygesen1, Klaus Kaae Andersen1, Ann Tabor4, Robert J Kurman5, Susanne K Kjaer6. 1. Unit of Virus, Lifestyle and Genes, Danish Cancer Society Research Center, Strandboulevarden 49, 2100 Copenhagen, Denmark. 2. Department of Pathology, The Johns Hopkins University School of Medicine, Baltimore, MD, USA; Department of Gynecology & Obstetrics, The Johns Hopkins University School of Medicine, Baltimore, MD, USA. 3. Department of Pathology, Copenhagen University Hospital, Kettegård Allé 30, 2650 Hvidovre, Denmark. 4. Center of Fetal Medicine, Department of Obstetrics, Juliane Marie Centre, Copenhagen University Hospital, Blegdamsvej 9, 2100 Copenhagen, Denmark. 5. Department of Pathology, The Johns Hopkins University School of Medicine, Baltimore, MD, USA; Department of Gynecology & Obstetrics, The Johns Hopkins University School of Medicine, Baltimore, MD, USA; Department of Oncology, The Johns Hopkins University School of Medicine, Baltimore, MD, USA. 6. Unit of Virus, Lifestyle and Genes, Danish Cancer Society Research Center, Strandboulevarden 49, 2100 Copenhagen, Denmark; Gynecologic Clinic, Juliane Marie Centre, Copenhagen University Hospital, Blegdamsvej 9, 2100 Copenhagen, Denmark. Electronic address: susanne@cancer.dk.
Abstract
OBJECTIVE: To describe the study population and estimate overall survival of women with a serous "borderline" ovarian tumor (SBT) in Denmark over 25 years relative to the general population. METHODS: The Danish Pathology Data Bank and the Danish Cancer Registry were used to identify 1487 women diagnosed with SBTs from 1978 to 2002. The histologic slides were collected from Danish pathology departments and reviewed by expert pathologists and classified as SBT/atypical proliferative serous tumor (APST) or noninvasive low-grade serous carcinoma (LGSC). Associated implants were classified as noninvasive or invasive. Medical records were collected from hospital departments and reviewed. Data were analyzed using Kaplan-Meier and relative survival was estimated with follow-up through September 2, 2013. RESULTS: A cohort of 1042 women with a confirmed SBT diagnosis was identified. Women with stage I had an overall survival similar to the overall survival expected from the general population (p=0.3), whereas women with advanced stage disease had a poorer one (p<0.0001). This was evident both in women with noninvasive (p<0.0001) and invasive implants (p<0.0001). Only among women with advanced stage, overall survival of women with SBT/APST (p<0.0001) and noninvasive LGSC (p<0.0001) was poorer than expected from the general population. CONCLUSIONS: To date this is the largest nationwide cohort of SBTs where all tumors have been verified by expert pathologists. Only in women with advanced stage SBT, overall survival is poorer than in the general population which applies both to women with noninvasive and invasive implants as well as to women with SBT/APST and noninvasive LGSC.
OBJECTIVE: To describe the study population and estimate overall survival of women with a serous "borderline" ovarian tumor (SBT) in Denmark over 25 years relative to the general population. METHODS: The Danish Pathology Data Bank and the Danish Cancer Registry were used to identify 1487 women diagnosed with SBTs from 1978 to 2002. The histologic slides were collected from Danish pathology departments and reviewed by expert pathologists and classified as SBT/atypical proliferative serous tumor (APST) or noninvasive low-grade serous carcinoma (LGSC). Associated implants were classified as noninvasive or invasive. Medical records were collected from hospital departments and reviewed. Data were analyzed using Kaplan-Meier and relative survival was estimated with follow-up through September 2, 2013. RESULTS: A cohort of 1042 women with a confirmed SBT diagnosis was identified. Women with stage I had an overall survival similar to the overall survival expected from the general population (p=0.3), whereas women with advanced stage disease had a poorer one (p<0.0001). This was evident both in women with noninvasive (p<0.0001) and invasive implants (p<0.0001). Only among women with advanced stage, overall survival of women with SBT/APST (p<0.0001) and noninvasive LGSC (p<0.0001) was poorer than expected from the general population. CONCLUSIONS: To date this is the largest nationwide cohort of SBTs where all tumors have been verified by expert pathologists. Only in women with advanced stage SBT, overall survival is poorer than in the general population which applies both to women with noninvasive and invasive implants as well as to women with SBT/APST and noninvasive LGSC.
Authors: Jeffrey D Seidman; Robert A Soslow; Russell Vang; Jules J Berman; Mark H Stoler; Mark E Sherman; Esther Oliva; Andre Kajdacsy-Balla; David M Berman; Larry J Copeland Journal: Hum Pathol Date: 2004-08 Impact factor: 3.466
Authors: Cyllene R Morris; Lihua Liu; Anne O Rodriguez; Rosemary D Cress; Kurt Snipes Journal: Cancer Causes Control Date: 2013-01-13 Impact factor: 2.506
Authors: M Akeson; B-M Zetterqvist; K Dahllöf; A-M Jakobsen; M Brännström; G Horvath Journal: Int J Gynecol Cancer Date: 2008 May-Jun Impact factor: 3.437
Authors: Russell Vang; Charlotte G Hannibal; Jette Junge; Kirsten Frederiksen; Susanne K Kjaer; Robert J Kurman Journal: Am J Surg Pathol Date: 2017-06 Impact factor: 6.394
Authors: Deyin Xing; Yohan Suryo Rahmanto; Felix Zeppernick; Charlotte G Hannibal; Susanne K Kjaer; Russell Vang; Ie-Ming Shih; Tian-Li Wang Journal: Hum Pathol Date: 2017-09-02 Impact factor: 3.466
Authors: Michael Herman Chui; Deyin Xing; Felix Zeppernick; Zoe Q Wang; Charlotte G Hannibal; Kirsten Frederiksen; Susanne K Kjaer; Leslie Cope; Robert J Kurman; Ie-Ming Shih; Tian-Li Wang; Russell Vang Journal: Am J Surg Pathol Date: 2019-11 Impact factor: 6.394